The Gene Editing, Transduction and Nanotechnology (GET iN) Core is directed by Irina V. Budunova, MD, PhD, and co-directed by Associate Core Director, Alexander Y. Yemelyanov, MD, PhD. The major objective of the Gene Editing, Transduction and Nanotechnology Core is to provide innovative customized R&D solutions in cell engineering and gene expression modifications for in vitro and in vivo applications, including (i) generation/large scale production of synthetic viruses (lenti/retro viruses, adenoviruses and adeno-associated viruses), (ii) CRISPR/Cas9 applications (gene knock-down, gene knock-in, in-genome protein tagging, CRISPR-libraris) and (ii) custom cells engineering and generation of customized experimental models (ex: drug development, biomarker search, assessment of gene/protein functions and signaling pathways studies).
- Custom cells engineering and generation of customized experimental models for drug design, biomarker search, and assessment of gene/protein functions and signaling pathways studies.
- Engineering of primary cells and immortalized cell cultures with stably expressed DNA/RNA. Examples of target cells include primary and immortalized skin human and mouse cells (keratinocytes, fibroblasts, and melanocytes), primary bone marrow progenitors, human and mouse T and B cells, neurons and cardiomyocites, human IPSC, and any other cell types provided by customers.
- Generation of viral expressing vectors (ex: lentivirus, retrovirus, adenovirus), including vector design and production, and cloning of DNA/RNA of interest.
- Generation and large scale production of lentiviruses and retroviruses provided in two formats: standard titer: 107-108TU/mL high titer: 109-1010 TU/mL at customized amounts.
- Generation and large scale production of adenoviruses provided in flexible formats based on the customer requested amounts and titers with viral titer ranging 109 – 1012 TU/mL.
- Engineering of cells with custom CRISPR/Cas9 genome editing including gene knock-down, gene knock-in, mutagenesis, in-genome protein tagging, and CRISPR-libraries.
- Engineering of cells using CRISPR-epigenetic regulation of gene expression (requires customer’s consultation to start the project).
- Engineering of cells with gene knock-down using shRNA lentiviral libraries (Dharmacon, Sigma, Origene, Genecopaeia).
Irina V. Budunova, MD, PhD
Associate Professor of Dermatology and Urology
Alexander Y. Yemelyanov, MD, PhD
Associate Core Director
Research Assistant Professor of Medicine, Pulmonary Division
We welcome your interest in our core. Please contact Research Associate Pankaj Bhalla, PhD, for more information.
Pankaj Bhalla, PhD